iBio, Inc. appointed Molly Carr as Chief Medical Officer effective July 31, 2026. Dr. Carr brings extensive experience from Eli Lilly and GlaxoSmithKline in endocrinology and metabolic diseases. She receives a $470,000 annual base salary with a target bonus of 40% and was granted an inducement award of 430,000 stock options at an exercise price of $1.40 per share. The options vest 25% after one year and the remainder monthly over three years. iBio is a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic, and other diseases.
